Confo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.8M

  • Investors
  • 15

Confo Therapeutics General Information

Description

Operator of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies that stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry with novel pathway-selective agonists for improved therapeutic intervention.

Contact Information

Website
www.confotherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Technologiepark 30
  • Zwijnaarde
  • 9052 Ghent
  • Belgium

Confo Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Confo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 28-Jun-2022 $1.8M 000.00 Completed Generating Revenue
7. Grant 30-Mar-2021 00.000 000.00 Completed Generating Revenue
6. Grant 20-Jun-2019 00.000 000.00 Completed Generating Revenue
5. Early Stage VC (Series A) 01-May-2019 000.00 000.00 0000 Completed Generating Revenue
4. Grant 20-Feb-2018 00.000 00.000 Completed Generating Revenue
3. Grant 01-Feb-2017 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 01-Feb-2016 $7.28M $7.28M Completed Generating Revenue
1. Spin-Off 01-Jan-2015 Completed Startup
To view Confo Therapeutics’s complete valuation and funding history, request access »

Confo Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class B2 0,000,000 00.00 00.00 00 00.00 00.000
Class B 000,000 00.00 00.00 00 00.00 00.000
To view Confo Therapeutics’s complete cap table history, request access »

Confo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a
Drug Discovery
Ghent, Belgium
65 As of 2023
000.00
0000000000 000.00

000000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

000000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confo Therapeutics Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 Formerly VC-backed La Jolla, CA 000 00000 000000000 00000
0000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
You’re viewing 5 of 60 competitors. Get the full list »

Confo Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 10

    Pending

  • 000

    Expiring in next 12 mo

Confo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220276244-A1 Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs Pending 29-Apr-2019 0000000000
US-20220244254-A1 Screening methods and assays for use with transmembrane proteins, in particular with gpcrs Pending 29-Apr-2019 0000000000
AU-2020266012-A1 Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs Pending 29-Apr-2019 0000000000
AU-2020266750-A1 Screening methods and assays for use with transmembrane proteins, in particular with gpcrs Pending 29-Apr-2019 0000000000
EP-3963328-A1 Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs Pending 29-Apr-2019 G01N33/566
To view Confo Therapeutics’s complete patent history, request access »

Confo Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Cedric Ververken Ph.D Chief Executive Officer & Board Member
Paolo Vicini Ph.D Chief Development Officer
Christel Menet Ph.D Chief Scientific Officer
Stephen Dowd Chief Business Officer
Toon Laeremans Ph.D Co-Founder & Head of Technology
You’re viewing 5 of 9 executive team members. Get the full list »

Confo Therapeutics Board Members (19)

Name Representing Role Since
Andrew Rice MD Self Chairman of Medical Advisory Board 000 0000
Caroline Goddeeris Ph.D Fund+ Board Member 000 0000
Cedric Ververken Ph.D Confo Therapeutics Chief Executive Officer & Board Member 000 0000
Christina Takke Ph.D V-Bio Ventures Board Member 000 0000
Dieter Weinand Self Chairman 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Confo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confo Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGeneration Ventures Venture Capital Minority 000 0000 000000 0
Fund+ Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Wellington Partners Venture Capital Minority 000 0000 000000 0
Vlaanderen verbeelding werkt Limited Partner 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial